China News Online, June 21st (Reporter Chen Jing) As a national first-class new drug, Phuket Hua ® (Platinib Capsules) has been approved to supply medicine to about 80 pharmacies in nearly 70 cities across the country from the 21st.

On the same day, Phuket Hua issued nearly 200 prescriptions in nearly 100 hospitals.

　　It is reported that the incidence of lung cancer has continued to increase in China in recent years.

The number of new cases of lung cancer and the number of deaths caused by lung cancer are numerous every year.

NSCLC is a highly heterogeneous malignant tumor with a very complex gene mutation spectrum, accounting for 80%-85% of all types of lung cancer.

In China, there are a large number of new RET fusion-positive lung cancer patients every year.

　　The drug will benefit adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-containing chemotherapy and have a positive RET gene fusion.

The RET gene, the rearrangement gene during transfection, is a lung cancer driver gene.

According to investigations, there has been no report before the selective RET inhibitors have been approved for marketing in China.

　　Most patients with RET mutations are already in the advanced stage of the disease when they are diagnosed, and there has been a lack of effective clinical treatment options for a long time.

"Before the approval of the market, the existing treatment programs for RET fusion-positive non-small cell lung cancer patients were not effective." Professor Wu Yilong from Guangdong Provincial People's Hospital told reporters.

Professor Wu Yilong is the main researcher of global clinical research.

This study aims to evaluate the safety, tolerability and effectiveness of pratinib in patients with related advanced solid tumors.

　　Clinical research data show that Pugeta® has strong anti-tumor activity and good safety and tolerability for NSCLC patients with RET fusion-positive.

“Phuket Hua ® is convenient to take orally once a day, which greatly improves patient compliance, and we hope that more patients will benefit from it,” said Professor Wu Yilong.

　　During the interview, the reporter learned that at present, there are still a large number of unmet needs of cancer patients in China in terms of drug accessibility, payment accessibility, service accessibility, and medication compliance.

Relevant pharmaceutical companies will join hands with a comprehensive service platform for medical treatment, medication, and payment to jointly promote the availability of Phuket Huan after its listing in China.

　　Zhao Ping, general manager of the Greater China region of the relevant pharmaceutical company, told reporters that the company is currently actively exploring the application of Pugeta® in other indications and expects more Chinese patients to benefit in the future.

(Finish)